RyboDyn Inc.
Kerry Wilson is a seasoned professional in the field of biotechnology, currently serving as Vice President and Co-Founder at RyboDyn Inc. since February 2023, as well as occupying roles such as Scientific Advisor and Chief Technology Officer. In previous positions, Kerry held the title of Senior Team Lead at Nanogami from May 2024 to February 2025 and served as Director at 1859 Inc. from August 2020 to February 2023, where significant contributions included the development of a cell-based drug screening platform for a major pharmaceutical company. Additional experience includes being a Principal Scientist at Singular Genomics and a Senior Scientist at Omniome Inc., where Kerry developed innovative sequencing prototypes. Academic background includes a Ph.D. in Chemistry from the University of Central Florida, complemented by degrees from Clemson University and business studies at London Business School.
This person is not in any teams
This person is not in any offices
RyboDyn Inc.
RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.